Nowak et al. Am J Nephrol 2016;44: (DOI: / )

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

Date of download: 7/11/2016 From: Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Ann Intern Med. 2013;159(6):

© 2016 S. Karger AG, Basel. All rights reserved Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency.

November 3, 2012 N Engl J Med DOI: /NEJMoa

The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.

Characteristics IgAN (n=28) ADPKD (n=37) Male (percentage) 21 (75.0)

Three Decades of Atherosclerotic Reno-vascular Disease Management - Changing Outcomes in an Observational Study Kidney Blood Press Res 2016;41:

The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy Kidney Blood Press Res 2016;41: DOI: /

Glomerular hyperfiltration is a common risk factor for accelerated GFR decline in young adults with autosomal polycystic kidney disease (ADPKD) G. Gentile.

Renal Parenchymal Hypoxia, Hypoxia Response and the Progression of Chronic Kidney Disease Am J Nephrol 2008;28:998– DOI: / © 2008.

Your First and Last Name* and Supervisor’s First and last name

Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease: Reliable Indicators of Vasopressin Activity and Disease Prognosis?

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Locatelli et al. Am J Nephrol 2017;45: (DOI: / )

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Figure 6 Effects of adiponectin on podocyte function

Figure 4 The theoretical contribution of genetic and

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Fan et al. Am J Nephrol 2017;45: (DOI: / )

Kuwabara et al. Am J Nephrol 2017;45: (DOI: / )

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Bhandari et al. Am J Nephrol 2017;45: (DOI: / )

Nat. Rev. Nephrol. doi: /nrneph

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology.

Management of hypertension in patients with chronic kidney disease

Nat. Rev. Nephrol. doi: /nrneph

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J.

Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease

Figure 4 Model of changes in the serum levels

Hammoud et al. Am J Nephrol 2016;44: (DOI: / )

Volume 92, Issue 4, Pages (October 2017)

Robert W. Schrier, Kimberly K. McFann, Ann M. Johnson

Jason T. Lee, MD, Vinit N. Varu, MD, Kenneth Tran, BS, Ronald L

Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease

Matei Neagu, PhD, Daniel Coca, PhD, Albert C.M. Ong, DM

Nat. Rev. Nephrol. doi: /nrneph

Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument Dorothee Oberdhan, Jason.

Figure 6 Hypothetical effect of starting therapy for autosomal

Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Predictors of disease progression in patients with CKD

Volume 93, Issue 3, Pages (March 2018)

Enrollment and Outcomes

Langsford et al. Am J Nephrol 2017;45: (DOI: / )

Payan Schober et al. Am J Nephrol 2017;45: (DOI: / )

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Classification by HtTKV0 and age at HtTKV0 predicts the change in eGFR over time in class 1 patients. Classification by HtTKV0 and age at HtTKV0 predicts.

Copyright © 2013 Elsevier Inc. All rights reserved.

Targeting Immunity in End-Stage Renal Disease

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Volume 67, Issue 2, Pages (February 2005)

Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Recurrent Vascular Access Dysfunction as a Novel Marker of Cardiovascular Outcome and Mortality in Hemodialysis Patients Kim et al. Am J Nephrol 2016;44:71-80.

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Calcifications in autosomal dominant polycystic kidneys.

Ann M. O'Hare, MA, MD American Journal of Kidney Diseases

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Volume 67, Issue 4, Pages (April 2005)

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Volume 68, Issue 5, Pages (November 2005)

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan-Meier table analysis of patients with corticobasal degeneration after onset of symptoms; the y axis refers to proportion of patients who are alive.

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Presentation transcript:

Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease Nowak et al. Am J Nephrol 2016;44:171-178 (DOI:10.1159/000448695) Table 1. Clinical characteristics of VEO and non-VEO patients with ADPKD at the final time point

Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease Nowak et al. Am J Nephrol 2016;44:171-178 (DOI:10.1159/000448695) Table 2. Median time to events for included VEO and non-VEO patients with ADPKD

Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease Nowak et al. Am J Nephrol 2016;44:171-178 (DOI:10.1159/000448695) Fig. 1. Kaplan-Meier curve of hypertension (a), htTKV ≥600 ml/m (b), glomerular hyperfiltration (eGFR ≥140 ml/min/1.73 m2; c) and eGFR <90 ml/min/1.73 m2 (d) according to group (VEO or non-VEO ADPKD). VEO patients were more likely to develop hypertension, to progress to htTKV >600 ml/m and to decline to eGFR <90 ml/min/1.73 m2 than non-VEO patients, but did not differ in progression to glomerular hyperfiltration.